16 unknown, 11 recruiting, 7 not yet recruiting, 2 completed. 33 Phase 2, 12 Phase 1, 3 Phase 3.
Follow SHR-1701: new trials by email Literature Review of SHR-1701 trials Research Report on SHR-1701
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II Trial Retlirafusp alfa, Famitinib malate, Gemcitabine & oxaliplatin - Intrahepatic Cholangiocarcinoma (Icc), Neoadjuvant Therapy | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 81 | 2026-09-30 | 2026-10-28 |
| GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Metastatic PDAC SHR-1701, Apatinib, gemcitabine - Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Recruiting | West China Hospital | 45 | 2026-09-21 | 2026-11-09 |
| Gemcitabine and Albumin-Bound Paclitaxel Combined With Liposomal Irenotecan (II) With or Without SHR-1701 as Neoadjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer SHR-1701, liposomal irinotecan+nab-paclitaxel+gemcitabine - Pancreas Ductal Adenocarcinoma | Phase 2 | Active not recruiting | The First Hospital of Jilin University | 62 | 2026-07-30 | 2026-09-08 |
| Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer COPOX, Radiotherapy, SHR-1701 - Gastric Cancer (GC), Gastroesophageal Junction Adenocarcinoma | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 60 | 2026-07-01 | 2026-07-08 |
| SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis SHR-1701, Capecitabine, S-1 - Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma | Phase 2 | Recruiting | Ruijin Hospital | 60 | 2026-04-24 | 2026-07-23 |
| SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer SHR-1701, apatinib, S-1 & Oxaliplatin - Gastric Adenocarcinoma | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 80 | 2026-04-03 | 2026-07-16 |
| Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma SHR-1701, Famitinib - Melanoma | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 70 | 2026-04-01 | 2026-04-08 |
| Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer SHR-1701, SHR-8068, Short-course radiotherapy - Locally Advanced Colorectal Cancer | Phase 2 | Not yet recruiting | Fudan University | 134 | 2026-04-01 | 2026-03-31 |
| SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC SHR-1701 + SBRT, SBRT - Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer) | Phase 2 | Recruiting | Fudan University | 66 | 2026-03-02 | 2026-04-30 |
| SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure SHR-1701+Rivoceranib + SHR-2554, SHR-1701 + Rivoceranib - Gastric Cancer (GC), Gastroesophageal Junction Adenocarcinoma | Phase 2 | Recruiting | Jingdong Zhang | 40 | 2026-01-01 | 2025-12-31 |
| A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer fuzuloparib, Famitinib, SHR-1701 - Ovarian Cancer | Phase 2 | Not yet recruiting | Qinglei Gao | 104 | 2025-12-30 | 2026-01-21 |
| Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects SHR2554; SHR-A2102, SHR2554; Adabelimumab, SHR2554; SHR-1701 - Locally Advanced or Metastatic Non-small Cell Lung Cancer | Phase 2 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 200 | 2025-10-09 | 2025-11-18 |
| Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma SHR2554 Tablets, SHR-A1811 Injection, SHR-A1904 Injection - Advanced Gastric Cancer, Metastatic Gastric Cancer | Phase 2 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 351 | 2025-09-05 | 2025-09-10 |
| Cryoablation Combined With SHR-1701 Plus Famitinib in Patients With Advanced Intrahepatic Cholangiocarcinoma. SHR-1701, Famitinib, Cryoablation - Advanced Intrahepatic Cholangiocarcinoma | Phase 2 | Not yet recruiting | Fudan University | 36 | 2025-09-01 | 2025-08-28 |
| PDL1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer SHR1701, SHR2554, CAPOX - Advanced Gastric Cancer, SHR1701 | Phase 2 | Recruiting | The First Affiliated Hospital of Zhengzhou University | 78 | 2025-06-15 | 2026-09-01 |
| Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping Trastuzumab, Adebrelimab, Apatinib - Gastric Cancer, HER2 + Gastric Cancer | Phase 2 | Not yet recruiting | China Medical University, China | 140 | 2025-05-01 | 2025-03-18 |
| SHR-1701 Combined with SHR2554 and BP102 for MCRC SHR-1701, BP102, SHR2554 - Colorectal Cancer Metastatic | Phase 2 | Not yet recruiting | Fudan University | 20 | 2024-12-01 | 2024-11-07 |
| SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma SHR2554+ SHR1701, SHR-1701 - Relapsed or Refractory Hodgkin Lymphoma | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 100 | 2023-06-14 | 2023-06-15 |
| Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer SHR-A1811 and SHR-1701, SHR-A1811 and capecitabine, SHR-A181, SHR-1701, and capecitabine - HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma | Phase 2 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 258 | 2023-03-14 | 2026-02-12 |
| Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer Almonertinib combined with SHR-1701, Almonertinib - Relapsed or Advanced Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 160 | 2022-10-01 | 2022-08-17 |
Showing 20 of 40. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (5) · Stomach Neoplasms (4) · Neoplasm Metastasis (3) · Melanoma (2) · Nasopharyngeal Carcinoma (2) · Pancreatic Neoplasms (2) · Recurrence (2) · Breast Neoplasms (1) · Cholangiocarcinoma (1) · Cirrhosis, Familial, with Pulmonary Hypertension (1) · Hodgkin Disease (1) · Lung Neoplasms (1) · Lymphoma (1) · Ovarian Neoplasms (1) · Prostatic Neoplasms (1)
Jiangsu HengRui Medicine Co., Ltd. (12) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (6) · Fudan University (5) · Chinese PLA General Hospital (2) · The First Affiliated Hospital with Nanjing Medical University (2) · Atridia Pty Ltd. (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · China Medical University, China (1) · Jingdong Zhang (1) · Qinglei Gao (1) · Ruijin Hospital (1) · Shandong Cancer Hospital and Institute (1) · Shanghai Chest Hospital (1) · Shanghai Zhongshan Hospital (1) · The First Affiliated Hospital of Zhengzhou University (1)
China (29) · Australia (1)
Dan Cao (1) · Feng Cheng, MD (1) · Jifeng Feng, MD (1) · JinMing Yu, PhD (1) · Jing Jin, M.D. (1) · Lin Shen, MD (1) · Weidong Han, PhD (1) · Xiao-Long Fu (1) · Yanan Zheng (1) · Yilong Wu, MD (1) · Zhi-Ming Shao (1)
PMID 33570247, PMID 35653122, PMID 36280870, PMID 39422697, PMID 41422078, PMID 42303632